NCT05033587View on ClinicalTrials.gov

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

PHASE2UnknownINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

May 1, 2023

Study Completion Date

November 1, 2023

Conditions
MGMT-Unmethylated Glioblastoma
Interventions
DRUG

Anlotinib

Anlotinib a multi-target receptor tyrosine kinase inhibitor.

DRUG

AK105

AK105 is a humanized monoclonal antibody that specifically binds to PD-1.

RADIATION

Radiotherapy

The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.

Trial Locations (1)

210008

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER